Bempedoic acid/ezetimibe - Esperion Therapeutics

Drug Profile

Bempedoic acid/ezetimibe - Esperion Therapeutics

Alternative Names: ETC 1002/Ezetimibe - Esperion Therapeutics

Latest Information Update: 16 Nov 2015

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dyslipidaemias

Most Recent Events

  • 05 Nov 2015 Esperion announces intention to submit IND to US FDA in 1H 2016
  • 01 Aug 2015 Preclinical trials in Dyslipidaemias in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top